array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Regeneron Pharmaceuticals Inc"
["slug"]=>
string(38) "c469a-us-regeneron-pharmaceuticals-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77"
["description"]=>
string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. "
["address_street"]=>
string(25) "777 Old Saw Mill River Rd"
["address_place"]=>
string(9) "Tarrytown"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1988-02-08"
["website_domain"]=>
string(13) "regeneron.com"
["website_url"]=>
string(25) "https://www.regeneron.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(10368)
["article_count"]=>
int(2445)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(63) "US Intensifies Drug Discount Debate in Latest Regeneron Lawsuit"
["snippet_en"]=>
string(218) "New Justice Department allegations that Regeneron Pharmaceuticals Inc. artificially inflated Medicare reimbursement rates on a high-earning eye treatment are likely to trigger copycat complaints at other manufacturers."
["url"]=>
string(105) "https://news.bloomberglaw.com/us-law-week/us-intensifies-drug-discount-debate-in-latest-regeneron-lawsuit"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/435ec56d-4f91-4384-b5ae-96baa87ad0ff"
["source"]=>
string(16) "bloomberglaw.com"
["publication_date"]=>
string(10) "2024-04-12"
["categories"]=>
array(4) {
[0]=>
string(31) "Financial Update/Profit Warning"
[1]=>
string(12) "Slash Prices"
[2]=>
string(5) "Legal"
[3]=>
string(11) "US Politics"
}
}
[1]=>
array(7) {
["title_en"]=>
string(92) "US Department of Justice files complaint against Regeneron, alleging fraudulent drug pricing"
["snippet_en"]=>
string(167) "The US Department of Justice said on Wednesday that it had filed a complaint under the False Claims Act against Regeneron Pharmaceuticals, alleging that the company..."
["url"]=>
string(196) "https://es.marketscreener.com/cotizacion/accion/REGENERON-PHARMACEUTICALS-10649/noticia/El-Departamento-de-Justicia-de-EE-UU-presenta-una-denuncia-contra-Regeneron-alegando-precios-fraud-46408681/"
["image_url"]=>
NULL
["source"]=>
string(18) "marketscreener.com"
["publication_date"]=>
string(10) "2024-04-10"
["categories"]=>
array(3) {
[0]=>
string(10) "Complaints"
[1]=>
string(5) "Fraud"
[2]=>
string(5) "Legal"
}
}
[2]=>
array(7) {
["title_en"]=>
string(78) "US Justice Department files suit against Regeneron for fraudulent drug pricing"
["snippet_en"]=>
string(155) "The U.S. Department of Justice said Wednesday that it has filed a lawsuit against Regeneron Pharmaceuticals for falsely reporting average selling prices..."
["url"]=>
string(187) "https://ch.marketscreener.com/kurs/aktie/REGENERON-PHARMACEUTICALS-10649/news/US-Justizministerium-erhebt-Klage-gegen-Regeneron-wegen-betrugerischer-Preisgestaltung-bei-Medikame-46408681/"
["image_url"]=>
NULL
["source"]=>
string(18) "marketscreener.com"
["publication_date"]=>
string(10) "2024-04-10"
["categories"]=>
array(3) {
[0]=>
string(10) "Litigation"
[1]=>
string(5) "Fraud"
[2]=>
string(5) "Legal"
}
}
[3]=>
array(7) {
["title_en"]=>
string(61) "Regeneron v Novartis and Vetter: Walker Process Client Update"
["snippet_en"]=>
string(301) "In an appeal that attracted a dozen amici, including the Department of Justice, the Federal Trade Commission, five states, and the District of Columbia, the Second Circuit gave the Walker Process antitrust doctrine a shot in the arm in a patent dispute related to pre-filled syringes(“ PFSs”) used"
["url"]=>
string(97) "https://www.natlawreview.com/article/regeneron-v-novartis-and-vetter-walker-process-client-update"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/98079a99-6a42-425f-81f5-97192631cfca"
["source"]=>
string(16) "natlawreview.com"
["publication_date"]=>
string(10) "2024-03-26"
["categories"]=>
array(2) {
[0]=>
string(9) "Antitrust"
[1]=>
string(5) "Legal"
}
}
[4]=>
array(7) {
["title_en"]=>
string(71) "US appeals court revives Regeneron's antitrust lawsuit against Novartis"
["snippet_en"]=>
string(258) "NEW YORK (Reuters) -A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders including permanent blindness. The 2nd U.S."
["url"]=>
string(76) "https://ca.news.yahoo.com/us-appeals-court-revives-regenerons-141546622.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/0ca9dd7e-b0ed-441e-96e8-bb1697c60801"
["source"]=>
string(9) "yahoo.com"
["publication_date"]=>
string(10) "2024-03-18"
["categories"]=>
array(7) {
[0]=>
string(8) "Verdicts"
[1]=>
string(14) "Product Launch"
[2]=>
string(5) "Legal"
[3]=>
string(21) "Competitive Behaviour"
[4]=>
string(10) "Litigation"
[5]=>
string(46) "Management of Legal and Regulatory Environment"
[6]=>
string(9) "Antitrust"
}
}
[5]=>
array(7) {
["title_en"]=>
string(59) "Greenburgh Sues to Block Edgemont Incorporation Legislation"
["snippet_en"]=>
string(300) "By Rick Pezzullo— The Greenburgh Town Board has taken legal action again to try to prevent Edgemont from becoming the town’s seventh incorporated village. During a special meeting Jan. 12, the board adopted a resolution hiring former state Supreme Court Justice Peter Sherwood to oppose a pending"
["url"]=>
string(93) "https://thehudsonindependent.com/greenburgh-sues-to-block-edgemont-incorporation-legislation/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/1ccb29a3-a184-41d5-b52d-53dbc628a772"
["source"]=>
string(24) "thehudsonindependent.com"
["publication_date"]=>
string(10) "2024-01-23"
["categories"]=>
array(4) {
[0]=>
string(5) "Legal"
[1]=>
string(11) "Legislation"
[2]=>
string(20) "Corporate Governance"
[3]=>
string(46) "Management of Legal and Regulatory Environment"
}
}
[6]=>
array(7) {
["title_en"]=>
string(57) "Regeneron surges after patent case ruling against Viatris"
["snippet_en"]=>
string(57) "Regeneron surges after patent case ruling against Viatris"
["url"]=>
string(120) "https://www.investing.com/news/stock-market-news/regeneron-surges-after-patent-case-ruling-against-viatris-432SI-3264127"
["image_url"]=>
NULL
["source"]=>
string(13) "investing.com"
["publication_date"]=>
string(10) "2023-12-27"
["categories"]=>
array(5) {
[0]=>
string(21) "Intellectual Property"
[1]=>
string(8) "Verdicts"
[2]=>
string(5) "Legal"
[3]=>
string(27) "Business Model & Innovation"
[4]=>
string(16) "Case Settlements"
}
}
[7]=>
array(7) {
["title_en"]=>
string(74) "Regeneron Gains After Eye-Drug Patent Victory Over Viatris - BNN Bloomberg"
["snippet_en"]=>
string(197) "Regeneron Pharmaceuticals Inc. rose the most in almost two months after a court ruled that the drugmaker’s patent rights were infringed by a cheaper copy of its eye drug developed by Viatris Inc."
["url"]=>
string(96) "https://www.bnnbloomberg.ca/regeneron-gains-after-eye-drug-patent-victory-over-viatris-1.2015908"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/934626b6-ebe5-4ae4-9ef1-c56964bc6283"
["source"]=>
string(15) "bnnbloomberg.ca"
["publication_date"]=>
string(10) "2023-12-27"
["categories"]=>
array(4) {
[0]=>
string(21) "Intellectual Property"
[1]=>
string(8) "Verdicts"
[2]=>
string(27) "Business Model & Innovation"
[3]=>
string(5) "Legal"
}
}
[8]=>
array(7) {
["title_en"]=>
string(38) "Market Trends Report 2023: Shohta Ueno"
["snippet_en"]=>
string(80) "Ueno of Regeneron talks about strategy for the unitary patent and UPC litigation"
["url"]=>
string(94) "https://www.managingip.com/article/2clb9fgrsvbx3uwszx2x2/market-trends-report-2023-shohta-ueno"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/1b85bda3-9e73-4d4d-b70f-4b038b46c130"
["source"]=>
string(14) "managingip.com"
["publication_date"]=>
string(10) "2023-12-18"
["categories"]=>
array(6) {
[0]=>
string(21) "Intellectual Property"
[1]=>
string(15) "Market Movement"
[2]=>
string(5) "Legal"
[3]=>
string(21) "Competitive Behaviour"
[4]=>
string(10) "Litigation"
[5]=>
string(5) "R & D"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(197)
}
[1]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(193)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(152)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(101)
}
[4]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(95)
}
[5]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(83)
}
[6]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(70)
}
[7]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(61)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(51)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(50)
}
[10]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(46)
}
[11]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(44)
}
[12]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(35)
}
[13]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(35)
}
[14]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(34)
}
[15]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(33)
}
[16]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(33)
}
[17]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(32)
}
[18]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(31)
}
[19]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(31)
}
[20]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(31)
}
[21]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(30)
}
[22]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(29)
}
[23]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(29)
}
[24]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(27)
}
[25]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(26)
}
[26]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(24)
}
[27]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(23)
}
[28]=>
array(2) {
["name"]=>
string(11) "Sponsorship"
["count"]=>
int(20)
}
[29]=>
array(2) {
["name"]=>
string(8) "Politics"
["count"]=>
int(20)
}
}
}
c469a-us-regeneron-pharmaceuticals-inc
Regeneron Pharmaceuticals Inc
Location
New York
Founded
1988-02-08
Website
https://www.regeneron.com
Articles
2445 Articles
Category
Pharmaceutical Preparations
Description
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
New Justice Department allegations that Regeneron Pharmaceuticals Inc. artificially inflated Medicare reimbursement rates on a high-earning eye treatment are likely to trigger copycat complaints at other manufacturers.
The US Department of Justice said on Wednesday that it had filed a complaint under the False Claims Act against Regeneron Pharmaceuticals, alleging that the company...
The U.S. Department of Justice said Wednesday that it has filed a lawsuit against Regeneron Pharmaceuticals for falsely reporting average selling prices...
In an appeal that attracted a dozen amici, including the Department of Justice, the Federal Trade Commission, five states, and the District of Columbia, the Second Circuit gave the Walker Process antitrust doctrine a shot in the arm in a patent dispute related to pre-filled syringes(“ PFSs”) used
NEW YORK (Reuters) -A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders including permanent blindness. The 2nd U.S.
By Rick Pezzullo— The Greenburgh Town Board has taken legal action again to try to prevent Edgemont from becoming the town’s seventh incorporated village. During a special meeting Jan. 12, the board adopted a resolution hiring former state Supreme Court Justice Peter Sherwood to oppose a pending
Regeneron Pharmaceuticals Inc. rose the most in almost two months after a court ruled that the drugmaker’s patent rights were infringed by a cheaper copy of its eye drug developed by Viatris Inc.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
